Oventus Medical Ltd

Oventus Medical — Thorney Technologies Ltd 2017 AGM

17 slides from Oventus Medical's conference presentation, Nov 24, 2017

  1. Slide 1: Oventus presentation for AGM of Thorney Technologies Ltd

    ASX Release For personal use only Oventus presentation for AGM of Thorney Technologies Ltd Brisbane, Australia 24th November 2017: Oventus Medical Ltd (ASX: OVN) is pleased to release a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors at the Annual

  2. Slide 2: For personal use only

    A clinical study completed earlier this year showed the company’s first generation product, the O2Vent MonoTM, is successful in treating Obstructive Sleep Apnoea (OSA) and that snoring was either For personal use only eliminated or significantly reduced to 100 per cent of patients. The positive resu

  3. Slide 3: Oventus: Innovators in Sleep Apnoea Treatment

    For personal use only Oventus: Innovators in Sleep Apnoea Treatment Presentation to investors at the 2017 AGM of Thorney Technologies Ltd (ASX: TEK) November 2017

  4. Slide 4: About Oventus

    About Oventus (ASX: OVN) For personal use only Oventus is commercializing its O2Vent technology to treat Obstructive Sleep Apnoea 2

  5. Slide 5: Titanium, 3D printed airway technology O2Vent

    Our titanium, 3D printed airway technology “O2Vent” enhances For personal use only treatment outcomes for more than half of OSA patients 3

  6. Slide 6: Without the need for one of these

    For personal use only Without the need for one of these 4

  7. Slide 7: Obstructive sleep apnoea… more than just a poor night's sleep

    Obstructive sleep apnoea… For personal use only more than just a poor night’s sleep 5

  8. Slide 8: Poor sleep has major impacts on health economics

    For personal use only Poor sleep has major impacts on health economics Number of sleep Financial losses in Australia attributed apnoea sufferers Australia between $40.1billion to loss understood to be 2016-2017 from of well-being in out of care right inadequate sleep 2016-2017 now 6

  9. Slide 9: The big business of sleep

    The big business of sleep For personal use only Obstructive Sleep Apnoea (OSA) is a massive market. It is worth US$3.8** globally, growing at a CAGR of 15-20%. ** In 2015: Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98. 7

  10. Slide 10: Only 20% of OSA sufferers are in care

    For personal use only Only 20% of OSA sufferers are in care. Why? Their inability to tolerate conventional treatment. 8 8

  11. Slide 11: Does this look comfortable to you?

    For personal use only Does this look comfortable to you? 9

  12. Slide 12: How Oventus Airway technology works

    How Oventus Airway technology works For personal use only The O2Vent technology is the first major innovation in the treatment of sleep apnoea for years 2. Air in on inhalation 1. delivered to throat, air out on exhalation Air goes in through the airway on inhalation and out through the airway on ex

  13. Slide 13: Compelling clinical data

    Compelling clinical data Patients experienced For personal use only significant improvement in In clinical trials (and in real life) our devices succeeded where snoring using others could not. O2Vent Oventus Airway Technology: • Makes mouth guards 30-50% more efficacious, and Patients experienced co

  14. Slide 14: Patients reported a good night's sleep for the first time in decades

    With Oventus’ oral device, many patients reported a good night’s sleep… for the first time in decades. For personal use only 12

  15. Slide 15: Distribution agreement with Modern Dental Group

    Distribution agreement with Modern Dental Group… the world’s largest distributor of dental prosthetics For personal use only Modern Dental is listed on HKSE TIcker: 3600 | Market cap: $2.21 b Has 25% coverage of all dentists in USA (34,000 dental offices through subsidiary, Microdental) Top 3 market

  16. Slide 16: Corporate snapshot

    For personal use only Corporate snapshot Oventus Medical Limited: ASX:OVN Capital Structure Shares on Issue 92.1m Options 3.84m Price (22/11/17) $0.61 Market Cap $56.20m Cash on hand (30/6/17) $8,663,000 Revenue FY17 $447,994 14

  17. Slide 17: For personal use only

    “| HAVE USED THE OVENTUS DEVICE FOR 3 YEARS AND IT IS AMAZING. Jeanne Marshail See more at www.oventus.com.au

Oventus Medical — Thorney Technologies Ltd 2017 AGM on 6ix